SinoMab BioScience Performance dei guadagni passati
Il passato criteri di controllo 0/6
SinoMab BioScience's earnings have been declining at an average annual rate of -1.1%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been declining at an average rate of 64.6% per year.
Informazioni chiave
-1.1%
Tasso di crescita degli utili
2.0%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 11.0% |
| Tasso di crescita dei ricavi | -64.6% |
| Rendimento del capitale proprio | -72.1% |
| Margine netto | -9,961.9% |
| Ultimo aggiornamento sui guadagni | 30 Jun 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Update: SinoMab BioScience (HKG:3681) Stock Gained 21% In The Last Year
Mar 04
What You Need To Know About SinoMab BioScience Limited's (HKG:3681) Investor Composition
Jan 28Did SinoMab BioScience Limited (HKG:3681) Insiders Buy Up More Shares?
Jan 01
Loss-Making SinoMab BioScience Limited (HKG:3681) Expected To Breakeven In The Medium-Term
Nov 30Ripartizione dei ricavi e delle spese
Come SinoMab BioScience guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Jun 24 | 2 | -200 | 82 | 124 |
| 31 Mar 24 | 3 | -221 | 90 | 130 |
| 31 Dec 23 | 4 | -243 | 98 | 135 |
| 30 Sep 23 | 5 | -259 | 98 | 150 |
| 30 Jun 23 | 5 | -274 | 99 | 165 |
| 31 Mar 23 | 5 | -279 | 91 | 173 |
| 31 Dec 22 | 4 | -284 | 83 | 180 |
| 30 Sep 22 | 19 | -301 | 108 | 186 |
| 30 Jun 22 | 34 | -318 | 134 | 191 |
| 31 Mar 22 | 30 | -303 | 134 | 195 |
| 31 Dec 21 | 27 | -288 | 133 | 199 |
| 30 Sep 21 | 20 | -222 | 94 | 172 |
| 30 Jun 21 | 13 | -156 | 55 | 146 |
| 31 Mar 21 | 13 | -139 | 63 | 124 |
| 31 Dec 20 | 13 | -123 | 72 | 103 |
| 30 Sep 20 | 6 | -217 | 86 | 166 |
| 30 Jun 20 | 0 | -311 | 100 | 229 |
| 31 Mar 20 | 0 | -294 | 81 | 222 |
| 31 Dec 19 | 0 | -276 | 62 | 214 |
| 31 Dec 18 | 1 | -84 | 9 | 47 |
Guadagni di qualità: 3681 is currently unprofitable.
Margine di profitto in crescita: 3681 is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: 3681 is unprofitable, and losses have increased over the past 5 years at a rate of 1.1% per year.
Accelerare la crescita: Unable to compare 3681's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: 3681 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).
Rendimento del capitale proprio
ROE elevato: 3681 has a negative Return on Equity (-72.09%), as it is currently unprofitable.